Skip to main navigation

Immunocore

Immunocore

Primary Menu

  • Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analysts Coverage
  • Corporate Governance
    • Document & Charters
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact Us

Primary Menu

  • Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analysts Coverage
  • Corporate Governance
    • Document & Charters
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact Us

News Releases

Breadcrumb

  1. Home /
  2. Investor Relations /
  3. News & Events /
  4. News Releases
11 May 2022
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
7 April 2022
Immunocore to present at the 21st Annual Needham Healthcare Conference
4 April 2022
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
9 March 2022
Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference
3 March 2022
Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
25 February 2022
Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
11 February 2022
Immunocore to present at the SVB Leerink Global Healthcare Conference
26 January 2022
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
6 January 2022
Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference
6 December 2021
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 136

Site - Shareholder Tools

Print Page
Email Alerts
RSS Feeds
Email Page

Immunocore

Immunocore

Site - Footer Social

  • About us
  • Our science
  • Our therapy areas
  • For patients
  • News
  • Careers
  • Contact us
  • Privacy and Social Media Guidelines
  • Cookies
  • Payments and Disclosures
  • Clinical trials

©2022 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd